Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Leap Therapeutics ( (LPTX) ) is now available.
Due to current market conditions and financial constraints, Leap Therapeutics has decided to complete the DeFianCe clinical trial and wind down its research and development activities, including the sirexatamab and FL-501 programs. The company will also reduce its workforce by approximately 75% in two phases, impacting key executives, and expects to incur $3.2 million in related costs. Leap Therapeutics is exploring strategic options to maximize shareholder value, including potential sales or partnerships, and has engaged Raymond James & Associates, Inc. as a financial advisor. The company reported updated data from the DeFianCe study, showing statistically significant improvements in progression-free survival among certain patient subgroups, but has decided to wind down the trial due to financial challenges.
The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.
Spark’s Take on LPTX Stock
According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.
Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.
To see Spark’s full report on LPTX stock, click here.
More about Leap Therapeutics
Leap Therapeutics, Inc. is a biotechnology company focused on developing targeted and immuno-oncology therapeutics. Its most advanced clinical candidate is sirexatamab (DKN-01), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being studied in patients with colorectal cancer. The company’s pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
Average Trading Volume: 2,185,579
Technical Sentiment Signal: Sell
Current Market Cap: $15.62M
For detailed information about LPTX stock, go to TipRanks’ Stock Analysis page.